{"name":"Foresee Pharmaceuticals Co., Ltd.","slug":"foresee-pharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"FP-025 capsules","genericName":"FP-025 capsules","slug":"fp-025-capsules","indication":"Other","status":"phase_2"},{"name":"Mirivadelgat","genericName":"Mirivadelgat","slug":"mirivadelgat","indication":"Other","status":"phase_2"},{"name":"linvemastat","genericName":"linvemastat","slug":"linvemastat","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"FP-025 capsules","genericName":"FP-025 capsules","slug":"fp-025-capsules","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mirivadelgat","genericName":"Mirivadelgat","slug":"mirivadelgat","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"linvemastat","genericName":"linvemastat","slug":"linvemastat","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQQ1RoLWM1Skk4Y2xOUUo1eDJkNFJhZWRZV2N0eEZmV2hfci1uS2tvVjRiNTV1TUVrWGVBMXZzc2J0dnpQS0xma0dKZ0lUUThZRzd6ZTJZZHUzVF85SE5VcGlrdG5iWUVpRHZrUEdrYkJGZURZQ2IwRl9TOHZwLVdVQ0NXc2R3dnRxUDdIcllNaC14RjBRZEg3MmQ0aHlhNllSbkVaSC12Vld5eU9ZX2NnNnhJdlRJamhiaXNZMHFMNmdkcE1rMlVzRkxRaUo5enhJbUtvTFBJTzN1WkxtUC03elZnUWllTlQ1QnE3YkNVNjd6WlZiSnZLWnIwSWRPdnpnYTAwUUJrbUlndy1hSlZlTGJ4ZEZtRnBIMVRMMFpR?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Appears Robust With 65+ Key Pharma Companies Actively Work","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNOERBcjd4V3Z1M1ExaUxHZXRYdDE1OGxPcE5BdmlaY1UwM05ydGQweWRDMnhrY0R6cnZhSW9SVnJXZ3ZuVEw2T01EdjJGcnY3ZkJ0MkRqR0swdHdZOVN4aHZBT2N5MDlaa09SUlVGZVFLaUpVTjdDeTJkTGZCemNtejBRNEFSWldkUk9VTjUxSEk3N1lCSGMyTE5BV09KNVVNbFBr?oc=5","date":"2026-01-28","type":"trial","source":"BioXconomy","summary":"Moderna does not ‘foresee investing’ in Phase III trials, says CEO - BioXconomy","headline":"Moderna does not ‘foresee investing’ in Phase III trials, says CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPR2FfemZsMl9RZW91c3ZiUFh2cWhVWUIwWnZkSkc0OXAxSmYwb09fTElzel9yX1c4SFJEcjk2Y2UxR2RlZjNzZjkyUjFrcWxvaTNuWjVwR1d0YVhQUmlHTExGTWhpVHFpNWNNVTNwZUVEMEs5aE5LV0dyNHdFVllFYU5tRHBaRTNRMjJqWTdIOFlja2NxZWJvYWV4dzEwWHgta3I1cEo4cmpzLWJsLWdqSDdfQzd3MkM4X2c?oc=5","date":"2026-01-09","type":"deal","source":"BioSpectrum Asia","summary":"Taiwan's Foresee Pharma inks $584.5M deal with Primevera Therapeutics - BioSpectrum Asia","headline":"Taiwan's Foresee Pharma inks $584.5M deal with Primevera Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOVE83cG41VGdaa2U0WnpzYUpxVDlBLUtCa05DaTlhOUVQQWtXaFRMbTlXTEFlbnNybGhiSWVOT01XZ25BN2YzRjhKdm83YVFUY3ZldjAyLVJQY1lwVXExSDl3VkNBSVY0SDI3MGxUcXpwajZOMjdoWDNkS3FLTDZWb050UC1LQXpJTjRCZ0dpZS0wQjNFcmVtN2k2enhHQldtNEZrMmItaVFrMXhQTGJBcWRoVFRDNHpYUklWOFk0UEZmeHl5MnZDUjQ5aWVDLWItQWNHb0FZZmszZFNrS2xSWGRXeXEyWGJzR0p4Z29EMUZkaUNfZlZRVG81bDVMS01yYWllakR1WmtBU3UzeHc?oc=5","date":"2025-10-21","type":"regulatory","source":"PR Newswire","summary":"Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | Del","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxOSWxxa2ZMUm01RFgwTkdxRVdsZWtEcW1xV0ZxT0x3UHUzY01QV19FcUc2d3NhWmV6alA0WGhlalkzZ252UVNoZ1BxcXJTVHdRYmRTQksyYXk2WWhIdDg3c3d1a3ppUThvOExxVDBzdENLXzh1M2UyQkRBMVFHMVllQ2o4YmtGNnNtNmpDM0RBbUdIMGlQcHlnNzY3YjlPMG1DUWs4cHVBbWhKMXB2cE9lcFlnRS11QWFrOXpkYWtyUEZSODJBTXNxcDZmZEFMcGJ4S24yOXVmNlpHR2k5WGRuQTg2YmNhTE0weEZaNFgyTW0?oc=5","date":"2025-09-08","type":"pipeline","source":"PR Newswire","summary":"Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxObDNxXy1TTlBBQ3hGOEV3TnN3UkVwNndxaDJzbkkwR0JUWGJaLTJuTGRyTHdvV055dF9SMjFSSTlMWkJMLWg3VGRjRlVOSmxkZWpyOXJXNWpDSEZCMFgwczVxRWZaeGVaTWJoZEhUQnd3b2xyWUNtTGlBS01DNDVxNWdGZ1VxUTFBWUhhRkJjamVCLWV6N1V4SllJakdmWkJNQm05dm9YWlhrdDQ?oc=5","date":"2025-08-29","type":"regulatory","source":"Contract Pharma","summary":"Foresee Announces FDA Approval of CAMCEVI ETM - Contract Pharma","headline":"Foresee Announces FDA Approval of CAMCEVI ETM","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOMmRoTDlBODNiVWM5ZHlRZDhQV084cjhnZXhqaTJxLVFERDdHOVJickZyazh3M1JiZkY3UzNZa2NadGlmZmxWY3dMRXlVOW4tRzJzRjROa1JfcGN3VWhNM0ltMWZORS1id1BHejBKZ09Gb044UDczaHp1NEVpR1lsZXpWMjZFREY4Vms2MkVJUllSeW5SQ3AxM1ZQeGVST3AxVEg2aElHNkFackxXcGFiRkN2SGhWVzN2ZnBPUVV4WQ?oc=5","date":"2025-08-29","type":"regulatory","source":"Pharmacy Times","summary":"FDA Approves 3-Month Leuprolide Mesylate 21-mg Formulation for Advanced Prostate Cancer - Pharmacy Times","headline":"FDA Approves 3-Month Leuprolide Mesylate 21-mg Formulation for Advanced Prostate Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNSkdoMEs5aUNKNmhGM25Ec1lXQkRfTkNUYWEtZGNlTElhTlFCZWY0VzlFRndUbjcxVjZiQUpMdGRZd3lUR0o5Y1BEeDhlbzZTdmI2cjIyak9vUjdBTFpMUlA2eGZhR205VncyRG1IQ1BFT2luNm9wTEFRV3Z4V1hUTVdmNDFNeVk0LS03Nkx3?oc=5","date":"2025-05-28","type":"pipeline","source":"Fortune Business Insights","summary":"Prostate Cancer Hormone Therapy Market Size, Share [2034] - Fortune Business Insights","headline":"Prostate Cancer Hormone Therapy Market Size, Share [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOX2RtNm9VZERjNEhoZzh1VzJ1alQtYTlVZTlOc2lIUjY1WkVNYTlFUF9CdjNaVDUzb19IYVh6X0swTzJ0Q0lfWTh5MWZLX3BhRDlwcUdScVg5eDdBZzFPVUZVNWFOeEpFWS1vbjJtYmVIcXFqVzZvUGRMeWkzMzlLT2JKTEh3T0NNTU9CalhINGtaWlZfVjJKc1Ixdw?oc=5","date":"2024-08-21","type":"pipeline","source":"BioPharma Dive","summary":"Employers foresee higher health costs next year due to rising pharmacy spend - BioPharma Dive","headline":"Employers foresee higher health costs next year due to rising pharmacy spend","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOZ3poUkpBMnRqRDh1dV9lS1pJRnEtd2t6OWZ5RnBqZnVYdVVjTHNBcnZQcm5ySkZwanFFR215ekt6c2NfeVRCOUJVelBjaFJJQ3k1Z3JmZXdIdThTNk5hOGFTUU9xXzhzckZjS0hteXBUaWdtVkZtQ19PeVRDUEx0UHlkbTJNNUtadXl6dzVPbHBmQ0VDamJFdmg4UFNoYVYtbFhrQ05CaWcybnBLVmNjX090VG8wWlhzUkIxUFRlWXlCbFUxMWVfR2E5ZnVHR3FfWVVTbTNPUEZ4cEgyODZQcw?oc=5","date":"2024-05-01","type":"earnings","source":"S&P Global","summary":"Peer Comparison: Top Pharmaceutical Companies Will See Revenues Soar By 2028 - S&P Global","headline":"Peer Comparison: Top Pharmaceutical Companies Will See Revenues Soar By 2028 - S&P Global","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFB0cWtSU2dGRkE1LTVlaFNoOGRncnVoTHFYT1AwOVdOT09OdXpvUUp3a3NqWldZS29iaS1SUlJFZXRNdzdBTlNaSU5pQlhnTFhhRjI1UjFWWlY1SmFxYS0zdGs2NVJOLUktdnNWYg?oc=5","date":"2022-09-12","type":"pipeline","source":"Wiley Online Library","summary":"Efficacy of FP-025: A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma - Wiley Online Library","headline":"Efficacy of FP-025: A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}